196 related articles for article (PubMed ID: 38844064)
1. Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody-drug conjugate development.
Ma Q; Durga P; Wang FXC; Yao HP; Wang MH
Drug Discov Today; 2024 Jun; 29(8):104057. PubMed ID: 38844064
[TBL] [Abstract][Full Text] [Related]
2. Exploring the next generation of antibody-drug conjugates.
Tsuchikama K; Anami Y; Ha SYY; Yamazaki CM
Nat Rev Clin Oncol; 2024 Mar; 21(3):203-223. PubMed ID: 38191923
[TBL] [Abstract][Full Text] [Related]
3. Introduction to Antibody-Drug Conjugates.
Pettinato MC
Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
5. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
6. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
7. Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review).
Sun T; Niu X; He Q; Liu M; Qiao S; Qi RQ
Mol Clin Oncol; 2023 Jun; 18(6):47. PubMed ID: 37206431
[TBL] [Abstract][Full Text] [Related]
8. Development of antibody-drug conjugates in cancer: Overview and prospects.
Ruan DY; Wu HX; Meng Q; Xu RH
Cancer Commun (Lond); 2024 Jan; 44(1):3-22. PubMed ID: 38159059
[TBL] [Abstract][Full Text] [Related]
9. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress.
Yao HP; Zhao H; Hudson R; Tong XM; Wang MH
Drug Discov Today; 2021 Aug; 26(8):1857-1874. PubMed ID: 34224904
[TBL] [Abstract][Full Text] [Related]
10. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
11. More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.
Schwach J; Abdellatif M; Stengl A
Front Biosci (Landmark Ed); 2022 Aug; 27(8):240. PubMed ID: 36042167
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibody drug conjugates: Making 1+1>2.
Gu Y; Wang Z; Wang Y
Acta Pharm Sin B; 2024 May; 14(5):1965-1986. PubMed ID: 38799638
[TBL] [Abstract][Full Text] [Related]
13. Recent Technological and Intellectual Property Trends in Antibody-Drug Conjugate Research.
Choi Y; Choi Y; Hong S
Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399275
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.
Sganga S; Riondino S; Iannantuono GM; Rosenfeld R; Roselli M; Torino F
J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763107
[TBL] [Abstract][Full Text] [Related]
16. Targeting cancer with antibody-drug conjugates: Promises and challenges.
Dean AQ; Luo S; Twomey JD; Zhang B
MAbs; 2021; 13(1):1951427. PubMed ID: 34291723
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs.
Metrangolo V; Engelholm LH
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275888
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance to Antibody-Drug Conjugates.
Collins DM; Bossenmaier B; Kollmorgen G; Niederfellner G
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897808
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
Peng H
Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
